Leonardo Brunetti· @Brunet3Leon · X·· 14 小时前评分70
正文 · 原文
Striking results from DeLLphi-305 in SCLC topped with an emotional standing ovation. Mainteinance Tarlatamab is actually more like a second induction-treatment rather than a proper mainteinance! Kudos to @sands_jacob for the magistral presentation
#ESMO26 #ESMOAmbassadors
34 浏览 · 1 赞 · 0 转发 · 0 回复
会议摘要
LBA3按 Presidential Symposium I 对上
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org来源：Leonardo Brunetti · x.com